1. Home
  2. BXMX vs NVAX Comparison

BXMX vs NVAX Comparison

Compare BXMX & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

BXMX

Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

HOLD

Current Price

$13.26

Market Cap

1.4B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$8.37

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BXMX
NVAX
Founded
2004
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.6B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BXMX
NVAX
Price
$13.26
$8.37
Analyst Decision
Hold
Analyst Count
0
9
Target Price
N/A
$11.33
AVG Volume (30 Days)
105.9K
3.4M
Earning Date
01-01-0001
05-07-2026
Dividend Yield
7.24%
N/A
EPS Growth
N/A
309.76
EPS
N/A
2.58
Revenue
N/A
$1,123,479,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$3.14
Revenue Growth
N/A
64.69
52 Week Low
$12.00
$5.80
52 Week High
$15.00
$11.85

Technical Indicators

Market Signals
Indicator
BXMX
NVAX
Relative Strength Index (RSI) 29.96 44.12
Support Level N/A $8.09
Resistance Level $14.64 $8.45
Average True Range (ATR) 0.21 0.41
MACD -0.07 -0.02
Stochastic Oscillator 0.65 39.80

Price Performance

Historical Comparison
BXMX
NVAX

About BXMX Nuveen S&P 500 Buy-Write Income Fund of Beneficial Interest

Nuveen S&P 500 Buy-Write Income Fund is a diversified closed-ended management investment company based in the United States. Its investment objective is to seek attractive total returns with less volatility. The fund invests its managed assets in a diversified equity portfolio that seeks to substantially replicate price movements of the S&P 500 Index. It also uses an index options of writing index call options in seeking to moderate the volatility of returns relative to an all-equity portfolio. Its revenue is generated mainly from interest and dividend income.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.

Share on Social Networks: